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Abstract
Background: Polycystic ovary syndrome (PCOS) is a widespread endocrine disorder,
affecting approximately 20% of women within reproductive age. It is associated
with hyperandrogenism, obesity, menstrual irregularity, and anovulatory infertility.
Melatonin is the main pineal gland hormone involved in the regulation of the circadian
rhythm. In recent years, it has been observed that a reduction in melatonin levels
of follicular fluid exists in PCOS patients. Melatonin receptors in the ovary and intra-
follicular fluid adjust sex steroid secretion at different phases of ovarian follicular
maturation. Moreover, melatonin is a strong antioxidant and an effective free radical
scavenger, which protects ovarian follicles during follicular maturation.
Objective: In this paper, we conducted a literature review and the summary of the
current research on the role of melatonin in PCOS.
Materials and Methods: Electronic databases including PubMed/MEDLINE, Web of
Science, Scopus, and Reaxyswere searched from their inception toOctober 2018 using
the keywords “Melatonin” AND “Polycystic ovary syndrome” OR “PCOS.”
Results: Based on the data included in our review, it was found that the administration
of melatonin can improve the oocyte and embryo quality in PCOS patients. It may also
have beneficial effects in correcting the hormonal alterations in PCOS patients.
Conclusion: Since metabolic dysfunction is the major finding contributing to the
initiation of PCOS, melatonin can hinder this process via its improving effects on
metabolic functions.
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1. Introduction
Polycystic ovary syndrome (PCOS) is a complex
disorder arising from the interaction of genetic
and environmental reasons that affects up to 20%
of women at reproductive age (1). According to
the ESHRE/ASRM consensus, at least two of the
following three features should be present for
proper PCOS diagnosis: 1) ovulatory dysfunction
(oligoanovulation and/or anovulation); 2) hyperan-
drogenemia (the biochemical feature of androgen
excess) or hyperandrogenism (the clinical feature
of androgen excess); 3) polycystic appearance of
ovaries in ultrasonography (2), together with the
exclusion of other etiologies (3). In addition to
reproductive and cosmetic sequelae, PCOS syn-
drome is associated with a higher risk of metabolic
disorders including insulin resistance, increased
oxidative stress (4), cardiovascular disease, type 2
diabetes mellitus, liver disease, and endometrial
cancer (5, 6).
Women with PCOS often seek treatment due
to their complaints of infertility and menstrual
cycle irregularities which are the results of chronic
oligo/anovulation (7). Changing lifestyles, such as
nutritional counseling and weight loss are the
necessary step of all treatment plans (8). Despite
the many advances in the understanding of the
Pathobiology and treatment strategies of PCOS
over the past decades, many questions remain to
be answered and the treatment of the syndrome
remains empirical.
Melatonin (N-acetyl-5-methoxytrypamine) is an
indolamine hormone that was firstly recognized
in the 1950s (9). Melatonin levels are regulated
by photoperiod as its production and secretion
are promoted at night in response to darkness
since light can suppress its secretion (9). Melatonin
is also produced in other organs such as the
gastrointestinal tract, skin, retina, bone marrow,
and lymphocytes (10, 11). It seems that mitochondria
are the site of melatonin synthesis within cells.
Moreover, the female reproductive organ, including
the follicular cells, oocytes, and cytotrophoblasts
are also among the melatonin production sites
(12). Several studies have shown the involvement
of melatonin in the pathogenesis of diabetes,
cancer, Alzheimer’s disease, immune and cardiac
diseases (13-15). Melatonin has been identified to
have different pharmacological properties such as
antioxidant, immunomodulatory, anti-angiogenic,
and oncostatic effects (16). Melatonin acts as
an inhibitory factor on the hypothalamic pituitary
gonadal axis (17). Melatonin receptors are trans-
membrane G-protein-coupled receptors including
melatonin receptor 1 (MT1; MTNR1A) and melatonin
receptor 2 (MT2; MTNR1B) (18).
The effects of melatonin on female reproduc-
tive physiology are mediated via its receptors
in hypothalamic, pituitary, and ovarian sites (19).
Melatonin is also a potent free radical scavenger
that exerts protective effects in female reproductive
organs; for instance, it is involved in the protection
of the oocyte against oxidative stress, particularly
at the time of ovulation. It can also be used to
protect the developing fetus from oxidative stress
can be happened by melatonin (20). The levels of
melatonin in follicular fluid are higher than its levels
in the blood (21). The concentration of melatonin
in follicular fluid significantly rises as the follicles
become mature (22).
In this paper, we have made an effort to review
the possible roles of melatonin in the pathogen-
esis of PCOS as well as the potential melatonin-
centered therapeutic measures, which can be
recruited herein.
2. Materials and Methods
2.1. Search strategy
Related published articles were searched in the
following electronic databases: PubMed/MEDLINE,
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Web of Science, Scopus and Reaxys. All the
sources were searched from their inception to
October 2018 using the keywords “Melatonin” AND
“Polycystic ovary syndrome” OR “PCOS.”
2.2. Study selection
Titles and abstracts from the electronic
databases were scrutinized following the search
for the keywords, and the full-text papers which
were expected to match with our inclusion
criteria were obtained. The following specified
inclusion criteria were used: (1) studies that
used melatonin in context of PCOS or those in
which melatonin was somehow shown to be
related to any of the mechanisms involved in the
pathogenesis of PCOS; (2) papers with available
full texts; (3) Papers in English language only.
There was no limitation regarding the inclusion
of any human or animal models for PCOS or
cell lines researches. Furthermore, the following
exclusion criteria were applied: (1) no report
on the treatment with melatonin; (2) no report
with the PCOS disease; (3) no report on the
use of melatonin for treating PCOS in clinical
or animal models or cell lines researches; (4)
no report on the melatonin level alternation in
the different body biological fluids; (5) review
articles; and (6) non-English language articles
(Figure 1).
Figure 1. Flow diagram of the search strategy.
2.3. Data extraction
The papers, meeting all the aforementioned
criteria were reviewed separately to confirm
the reliability of the extracted data. All
characteristics of the articles such as author
name, year, study location, study population,
study period, treatment method, dose of
treatment, and outcomes were extracted
from the papers. The extracted data of
the selected studies are shown in Tables I
and II.
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3. Results
3.1. Study characteristics
After searching the aforementioned databases
with considered keywords, the papers were
reviewed by two authors. In the first step, titles
and abstracts were screened and 121 papers
that had enough connectivity with our keywords
were included. In the second step, full texts
were reviewed for the eligibility and relevance
of their findings, and 99 articles were excluded
due to duplicate data, non-English languages,
review articles, and insufficient relevance. Finally,
22 studies were selected, including studies
that have used melatonin administration for
treating PCOS in clinical and animal models of
PCOS and also the studies that have shown
alternation of melatonin levels involved in the
pathogenesis and diagnosis of PCOS; 22 articles
were included in the current review, including
15 clinical human studies and 7 animal studies.
Table I is related to the studies that indicate
the alternation of melatonin levels in different
biological fluids such as blood, serum, urine,
saliva, and follicular fluid in PCOS patients. Table II
is related to the studies that have used exogenous
melatonin as a drug for curing PCOS in sick
women, animal models, or cell lines researches.
And, the remaining studies are related to the
melatonin receptor gene polymorphisms in PCOS
patients.
3.2. PCOS pathogenesis
PCOS may be initiated by some specific abnor-
malities in the hypothalamus-pituitary compart-
ment, ovaries, adrenal gland, and the peripheral
compartment like adipose tissue (23). In PCOS
patients, an increase in gonadotropin-releasing
hormone (GnRH) pulse frequency enhances the
luteinizing hormone (LH) pulse frequency and
amplitude (24). In spite of elevated LH secretion,
follicle-stimulating hormone (FSH) levels remain
in the lower follicular range due to the negative
feedback of enhanced estrogen levels and follic-
ular inhibition (24). As a result of altered LH:FSH
ratio in PCOS women, the androgen production
by the theca cells in the ovaries is increased;
however, due to the low FSH levels, the follic-
ular maturation is dramatically impaired (25). In
addition, ovarian dysregulation of cytochrome-17,
defects in the aromatase activity of the ovarian
granulosa cells (GC), as well as the stimulation
of the ovarian theca cells by high levels of
insulin-like growth factor 1 (IGF-1) are among other
mechanisms involved in androgen overproduction
(26). Excessive adrenocortical secretion of dehy-
droepiandrosterone is observed in approximately
50-70% of PCOS patients (27). Increased peripheral
5 alpha-reductase activity and enhanced periph-
eral aromatization of androgens to estrogens that
induces the reversal of estrone to estradiol ratio
and a chronic hyperestrogenic state are also seen
in PCOS patients (28). There is general agree-
ment that insulin resistance and hyperinsuline-
mia play a major part in the pathogenesis of
PCOS (29). Hyperinsulinemia stimulates ovarian
theca cells and leads to androgen overproduc-
tion. Hyperinsulinemia along with hyperandrogen-
emia and enhanced levels of IGF-1 inhibit sex
hormone-binding globulin secretion, which surges
the levels of bioactive androgens and worsens
the clinical manifestations of androgen excess in
PCOS patients (29). Also, it has been discovered
that insulin resistance and hyperandrogenism can
affect normal function of adipocytes (30). Previous
researchers have found that adipose tissue dys-
function are associated to metabolic and reproduc-
tive dysfunction including insulin resistance and
androgen excess secretion in most PCOS patients
(31) (Figure 2).
https://doi.org/10.18502/ijrm.v17i12.5789 Page 871
International Journal of Reproductive BioMedicine Mojaverrostami et al.
3.3. Alternation of melatonin levels in
different body fluids of PCOS patients
Melatonin synthetic enzymes such as arylalky-
lamine N-acetyl-transferase and hydroxyindole-O-
methyltransferase have been identified in most
tissues including ovaries (10). Measurable levels of
melatonin have been identified in most biological
fluids, interestingly in the follicular fluid. The con-
centration of melatonin in preovulatory follicles is
higher than that of plasma suggesting its possible
direct effects on ovarian function (32).
In several studies, melatonin levels in PCOS
women have been measured to find its role in
the PCOS pathogenesis (Table I) (33, 34). The
most important metabolite of melatonin, urinary 6-
sulfatoxymelatonin (aMT6s), is considered to be a
good marker for melatonin production in the body
(35). The plasma concentrations of aMT6s in hyper-
androgenic and PCOS women were significantly
higher than healthy women possibly due to higher
melatonin production (35). It has been demon-
strated that testosterone and estrogen can regu-
late melatonin secretion. Melatonin secretion has
been shown to decrease in castrated rats due to
the reduction of testosterone levels (36). Ovariec-
tomized rats exposed to 17β-estradiol had reduced
numbers of α/β-adrenoreceptors, responsible for
the stimulation of melatonin production, in their
pinealocytes (37). Sex hormones can adjust the
human biological clock by affecting the hypotha-
lamic suprachiasmatic nucleus and pinealocytes
(38). In a study by Luboshitzky and colleagues,
PCOS women had higher levels of αMT6s, LH,
and testosterone than patients with idiopathic
hirsutism or the control groups. The results of
this study showed that αMT6s level inversely
related to testosterone level in PCOS disease.
However, this result seems contradictory because
other studies in PCOS introduced the direct rela-
tionship between αMT6s and testosterone (33).
Treatment with estradiol-cyproterone acetate nor-
malized the αMT6s levels in PCOS patients by
inhibiting androgens and gonadotropins (33). In
another study by the same group, women with
PCOS had higher aMT6s, testosterone, LH/FSH
ratio, and insulin values than women in the control
groups. Higher aMT6s levels were due to the ampli-
fication of melatonin production. In some studies,
testosterone was introduced as a determinant of
aMT6s level in PCOS patients (35). Melatonin has
been found to increase the secretion of proges-
terone and androgen in pre-antral follicles after
incubation for two weeks and in antral follicles
after a 30-hr incubation (39). In other studies,
the elevated melatonin levels in serum of PCOS
patients was found to be positively associated
with testosterone levels (40). Results from studies
show that melatonin levels in blood and saliva
along with the level of 6-sulfatoxymelatonin in
urine were significantly higher in PCOS patients
compared to the healthy women (41). The levels
of 6-sulfatoximelatonin in urine, nocturnal mela-
tonin levels in saliva (at 3:00 am), and melatonin
in the blood had a significant correlation with
the degree of sleep disorders (41). 8-hydroxy-2’-
deoxyguanosine (8-OHdG) is a marker of oxidative
damage to DNA that can be detected in urine
(42). In one study, the daytime urinary aMT6s
and 8-OHdG levels were similar in PCOS patients
and the control group, while the night-time levels
of these molecules were significantly higher in
PCOS patients than those of the control group
(42). During the night, PCOS women with raised
oxidative stress markers had higher levels of
8-OHdG and aMT6s. The production of higher
amounts of melatonin was probably for neutralizing
reactive oxygen species (ROS) at the night time.
Melatonin level in PCOS cases was shown to have
a significant correlation with the serum LH:FSH
ratio (40). In patients with higher LH:FSH ratios,
melatonin levels were significantly lower than the
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patients with lower ratios, indicating the inverse
correlation of LH:FSH ratio andmelatonin secretion
(40).
Different studies have indicated that PCOS
patients have higher serum levels of melatonin
(35, 40), therefore melatonin could be used as
a valuable marker for the prediction of PCOS.
It was suggested that the elevation of serum
melatonin in PCOS patients is due to the reduction
in its follicular fluid concentration (32) The role
of melatonin in oocyte maturation has been also
approved. Concentration of melatonin in the pre-
ovulatory follicles is higher than smaller immature
follicles, resulting in higher antioxidant capacity of
larger follicles (43). In PCOS patients, the decline
in the follicular concentration of melatonin is due
to the reduction in the uptake of melatonin from
circulation and an increase in the numbers of atretic
follicles (32). Follicular atresia could be seen in
PCOS patients due to increased oxidative stress
and follicular damage which occurs as a result
of the reduction in intra-follicular melatonin levels
(32). A great deal of research has shown that ROS
generation and lipid peroxidation are meaning-
fully higher in PCOS cases (44, 45). Along with
these changes, levels of superoxide dismutase,
catalase, and glutathione peroxidase are reduced,
which causes intense oxidative stress in ovarian
follicles (46). Melatonin is shown to be capable
of regulating the gene expression of antioxidant
enzymes, in addition to preventing apoptosis by
increasing Bcl2 and reducing Caspase 3 (47,
48). Terzieva and colleagues reported that mela-
tonin levels in women with PCOS in the morning
were significantly higher than at night time, and
the night-day difference of melatonin levels in
PCOS cases was lower than that of the healthy
group (49). However, a study reported conflicting
results stating that the total serum melatonin levels
were significantly lower in women with PCOS
(50).
3.4. Association of melatonin receptor
gene polymorphisms in PCOS patients
The positive effects of melatonin on different
tissues of the body are mediated by the melatonin
receptors 1A and 1B (18). The earliest study on the
association between common genetic variations of
melatonin receptors and the prevalence of PCOS
was conducted by Wang and colleagues (51). In
this study, four single nucleotide polymorphisms
(SNPs) (rs4753426, rs10830963, rs1562444, and
rs1279265) in MTNR1B gene were determined
and no differences in genotype and allelotype
frequencies for these SNPs were found neither
in the PCOS nor in the healthy women. In addi-
tion, they found a significant association between
the rs10830963 SNP and the concentration of
testosterone in PCOS patients. The amount of
testosterone, glucose, and insulin in the serums of
women with cytosine/guanine allele (CG) and gua-
nine/guanine allele (GG) genotypes were consider-
ably higher than the cytosine/cytosine allele (CC)
genotypes, which describes the possible effects
of DNA sequence variations of melatonin receptor
genes on the occurrence of PCOS. In subsequent
research that was performed on Chinese women,
the relationship between the pathogenesis of
PCOS and rs2119882 SNP, which is located in the
MTNR1A gene was evaluated. Genotype and allele
frequencies of rs2119882 were significantly differ-
ent between the PCOS cases and the controls;
the C allele frequency in the PCOS patients was
significantly higher than the control group which
confirms the association of SNP rs2119882 with
PCOS (52). In another study, an association of
two SNPs, rs10830963 and rs10830962 located
at the MTNR1B gene with PCOS, was examined.
Both genotypes and allelotypes occurrences of
the rs10830963 SNP in PCOS women were sig-
nificantly different compared to healthy women.
In addition, the occurrences of GG and GC were
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higher among PCOS women. According to the
results of the mentioned study, rs10830963SNP
is associated with the predisposition of women to
PCOS. No suggestive differences were observed
in the genotypes and allele distributions of the
other SNPs (rs10830962) between the PCOS and
the healthy women (53). Recently, Song and col-
leagues reported that there is a significant asso-
ciation between rs2119882 and the prevalence of
PCOS, although no association was found between
rs10830963 and PCOS (54). They reported that the
clinical and metabolic features of PCOS manifest
largely in CC genotype carriers than the TC and
TT genotypes. They also showed that there exists
a considerable difference in the transmission of
allele C of rs2119882 between obese and non-
obese PCOS patients.
3.5. Protective effects of exogenous
melatonin administration in PCOS
3.5.1. Metabolic function improvement by
melatonin
An improvement of metabolic function in PCOS
patients may enhance ovarian function. There has
been growing evidence suggesting the relation of
melatonin with glucose homeostasis and insulin
secretion. Peschke and colleagues have shown
a negative correlation between melatonin and
insulin levels in patients with type 2 diabetes
(55). Furthermore, several studies have shown
that melatonin administration can improve glucose
hemostasis, exert antihyperglycemic effects, and
improve endothelial vascular function in experi-
mental models of metabolic syndrome and type 2
diabetes (56). Faria and colleagues showed that
melatonin, through melatonin receptors 1 and 2,
activates a brain-liver communication and sup-
presses hepatic gluconeogenesis via peripheral
muscarinic receptors in rats (57). Evidence from
in-vitro studies have shown that glucose uptake
in adipocytes and skeletal muscle cells can be
increased by melatonin (58).
Letrozole is an aromatase inhibitor which is
largely used for treatment of breast cancer (34). In
2001, Letrozole, for the first time, was described as
an ovulation-inducting agent (35). Letrozole inhibits
androgens-to-estrogens conversion at the GC,
resulting in the reduction of estrogen levels, which
consequently releases the hypothalamus-pituitary
axis from its negative feedback and increases
the FSH secretion by pituitary stimulation (35). In
addition, an inhibition of aromatase activity at the
ovarian level increases intraovarian androgens that
improve follicular sensitivity (36). A meta-analysis
including 26 randomized controlled trials (5,560
women) concluded that letrozole therapy appears
to improve live birth and pregnancy rates in anovu-
latory PCOS patients compared with clomiphene
citrate (37, 38). Chottanapund and colleagues (59)
have evaluated the aromatase suppressive effects
of melatonin on hormonal positive breast cancer
cells and have shown that melatonin was as potent
as letrozole in inhibiting aromatization of androgen
to estrogen. Furthermore, in several studies, it has
been demonstrated that melatonin behaves as a
selective estrogen enzyme modulator (SEEM) and
a selective estrogen receptor modulator (SERM)
(40). Moreover, the aromatase-suppressive effect
of melatonin has been also shown in various cells,
such as breast cancer, glioma, and endothelial
cells (42). Several studies have demonstrated that
melatonin reduces obesity and restores adipokine
patterns and ameliorates the proinflammatory
state, which underlies the development of insulin
resistance (60). These findings all together show
that the use of melatonin due to its aromatase-
modulating activity, as well as its reducing effects
on hepatic gluconeogenesis, ameliorating the pro-
inflammatory state present in PCOS, improvement
of glucose uptake by peripheral tissues, and the
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subsequent reduction in insulin levels, may be
effective in the management of PCOS patients
(Table II).
3.6. Melatonin in PCOS patients
undergoing assisted reproductive
technology (ART) treatment
PCOS affects ART outcomes and controlled
ovarian hyperstimulation (COH) with conventional
protocols leads to a higher risk of ovarian hyper-
stimulation syndrome (OHSS) (61). Several studies
have demonstrated that the poor fertilization, low
oocyte, and embryo quality adversely influence
the clinical outcomes in PCOS patients undergoing
ART treatment (62). Insulin resistance of ovarian
GC and overexpression of vascular endothelial
growth factor (VEGF) due to insulin stimulation
are proposed to be the underlying mechanisms of
poor clinical outcomes (63). Melatonin may affect
ovarian microenvironment by improving insulin
resistance. In a randomized double-blind trial of
PCOS patients, the administration of melatonin
withmyo-inositol enhanced the oocyte and embryo
quality (64). The main goal in COH of PCOS
patients is to prevent OHSS. The only way to
prevent all type of OHSS in ART treatment is in-vitro
maturation (IVM) followed by in-vitro fertilization
(IVF) since this approach avoids the activation of
VEGF-mediated processes (65). However, despite
the extensive research conducted so far, IVM is
still a suboptimal procedure and the application
of IVM in infertility treatment remains immature
(66). The IVM involves additional procedures that
increase oxidative stress in oocytes and embryos
and reduce the developmental competence of
oocytes, in comparison to the conventional IVF (67).
The effects of melatonin on oocyte and embryo
quality and ART outcomes are discussed in the
following sections of this review.
3.7. Fertility and pregnancy
Recently, several studies evaluated the effects
of melatonin in the treatment of PCOS to improve
fertility and hormonal alterations. Lemos and col-
leagues have shown that rat models of PCOS
have lower weight gain during pregnancy and
show reduced numbers of implantation sites which
result in a decreased number of offspring. Also,
rat models of PCOS have higher collagen content
in the uterine horns which hinders the blastocyst-
endometrial interactions and reduces the implan-
tation rate (68). Co-treatment of melatonin and
metformin can reverse the reduced weight gain
and the high collagen fiber content of uterine horns
in the PCOS group, compared to the control group.
Moreover, the number and weights of the offspring,
the blastocyst-endometrium interactions, and the
fetal development were increased while the time
required for pregnancy was decreased (68). In
some recent studies, it has been reported that
oral administration of melatonin has no significant
effects on clinical pregnancy rate or oocyte and
embryo qualities (69).
3.8. Oocyte maturation
Follicular fluid melatonin produced by the
luteinizing GC in the late folliculogenesis period
has a substantial function in the growth and mat-
uration of mammalian oocytes (47). In the ovary,
melatonin receptors in granulosa-lutein cells can
regulate the function of this organ by controlling
progesterone secretion in addition to LH and
GnRH receptors gene expression via pathways
such as mitogen-activated protein kinase and
activation of Elk-1 (22). Melatonin concentrations
are significantly higher in larger follicles, particu-
larly in preovulatory follicles, due to participation
in the secretion of progesterone and maturation
of oocyte along with subsequent ovulation and
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luteinization events (70). Interestingly, intrafollicular
melatonin level is considerably lower in PCOS
women than the healthy women which may be the
reason for the anovulation and low oocyte quality
(32).
The supplementation of culture medium with
different substances can increase oocyte mat-
uration and IVF, as a remedy for reproductive
problems (71). Based on these findings, a number
of studies were designed, using supplementation
of culture media by melatonin to enhance oocyte
maturation and embryonic development. In a study
by Kim and colleagues, melatonin concentration
gradually increased in the culture media of GC
due to its production by GC. Also, the addition of
melatonin to IVM media improved the cytoplasmic
maturation of immature oocytes and increased
the rates of implantation (72). The amplification of
mRNA expression of the enzymes that participate
in melatonin production in cultured GC including
acetylserotonin O-methyltransferase (ASMT) and
aralkylamine N-acetyltransferase (AANAT) has also
been shown. PCOS results in anovulation and
is considered an important cause of IVF failure.
Melatonin along with other substances such as
myo-inositol was identified as a good predictor for
IVF outcomes, and their high concentrations were
an indicator of appropriate quality of oocytes (32).
Oral administration of melatonin in combination
with myo-inositol in PCOS patients enhanced the
quality of the oocyte and embryo, increased the
number of mature oocytes, and finally resulted
in an increased concentration of follicular fluid
melatonin (64). In another study, the beneficial
effect of melatonin on the quality of oocytes in
PCOS patients during IVM with different melatonin
concentrations was investigated. Also, melatonin
proved to be effective in the stimulation of nuclear
maturation of oocytes as well as in increasing
the cleavage rate via regulating free radicals to a
certain level required for increasing maturation rate
(73). This effect of melatonin on oocyte maturation
had a dose-dependent pattern in a manner that
lower doses were more effective on maturation
rate.
3.9. Histological changes in the ovary
In one study, the histopathological inspection
of the ovary and uterus showed reductions in
neoplastic endometrial glands and cystic follicles
in PCOS rats following melatonin treatment (56).
In another study, the administration of melatonin
reduced cystic follicles and thickness of the theca
layer and increased the number of corpus luteum
and the granulosa layer thickness (74). The reduc-
tion in the thickness of theca interna is due to the
action of melatonin on the reduction of androgen
production in the ovary (75). Melatonin showed
protective effects on corpus luteum against ROS
via its antioxidant effects (76). The absence of
melatonin in pinealectomized animals causes the
development of ovarian cysts due to the modifica-
tion of the synthesis of LH and FSH. Increase in the
LH levels is a major abnormality detected in PCOS
(77). Similarly, constant illumination, an induction
model of PCOS in rats, have shown permanent
estrous condition and polycystic ovaries aspect
(78). In one study, pinealectomy and continuous
light were used separately in female rats to induce
PCOS. In both of these methods, the production
of melatonin was diminished and PCOS condition
was observed. In the group treated with melatonin,
a significant reduction in the number and size
of cysts were observed, probably as a result of
the antigonadotrophic effects of melatonin (79).
Melatonin has shown protective effects against
metabolic and reproductive abnormalities in animal
models of PCOS (56, 80). Melatonin treatment in
PCOS patients significantly affects body character-
istics including reduced body weight, body mass
index, and intra-abdominal fat (56).
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3.10. Antioxidant effects
Several studies revealed that oxidative stress is
one of the main reasons for female reproductive
system disorders such as infertility, endometrio-
sis, and PCOS (81). This has been supported by
the fact that PCOS patients have higher levels
of oxidative stress compared to healthy women
(45, 82). It has been demonstrated that PCOS
patients are at risk of cardiovascular diseases due
to their higher exposure to oxidative stress and
the following undesirable effects such as blood
pressure and insulin resistance (45). Lemos and
colleagues showed that animal models of PCOS
induced by constant illumination had higher levels
of lipid peroxidation, which leads to increases in
oxidative stress, pro-oxidant enzymes, and pro-
inflammatory cytokines (83). Treatment with a com-
bination of metformin hydrochloride and melatonin
was shown to be advantageous in the PCOS
group by regulating plasmatic variables of oxidative
stress, for example, reduction of nitric oxide and
total glutathione levels. Furthermore, treatment
with melatonin apparently reduced liver toxicity,
pro-inflammatory cytokines, TNF-α and IL-1 and the
pro-inflammatory enzymes iNOS (83). Similarly, in
different studies, the antioxidant effect of melatonin
along with its inhibitory effects on pro-oxidant
enzymes and pro-inflammatory cytokines were
reported (84).
Melatonin supplementation to the culture
medium has been shown to increase the oocyte
maturation rate and reduce ROS production (85).
It can promote the expression of superoxide
dismutase and glutathione peroxidase (86); also,
melatonin is able to quench ROS and reactive
nitrogen species (RNS) (76). Scavenging action of
melatonin plays a valuable role during ovulation,
because ovulation is an inflammatory process,
and reactive species are generated and released
in the follicular fluid (87). Therefore, melatonin
quenches ROS and RNS and protects GC and
oocyte during ovulation (32). Studies have also
displayed that oxidative stress is detrimental to
oocyte maturation, since the activation of oxidative
stress pathway in follicular and IVM medium is
unavoidable due to cellular metabolism and lack
of antioxidant mechanisms, melatonin is a suitable
candidate to be added to the IVM medium (73,
88).
3.11. Melatonin and menstrual cyclicity
in PCOS
Menstrual cycle irregularities are among the
major complications of PCOS that affect the quality
of life of patients leading to infertility (89). The
altered steroid sex hormones in PCOS patients
affect the hypothalamic-pituitary-ovarian axis and
lead to the failure of follicular maturation and
ovulation (89). Furthermore, hyperinsulinemia and
insulin resistance cause ovarian dysfunction (90).
These events result in anovulation and inadequate
hormonal levels leading to irregularities in men-
strual cycle.
Melatonin seems to promote follicular matu-
ration and ovulation through the protection of
follicles against oxidative stress and their rescue
form atresia (40). After six months of melatonin
therapy in 40 normal-weight PCOS patients, men-
strual irregularities and hyperandrogenism were
improved. The lack of significant alterations in the
secretion of insulin and insulin sensitivity suggests
that melatonin may act on the ovary through
an independent mechanism (91). However, the
effect of long-term melatonin therapy with the aim
of menstrual cyclicity improvement needs to be
evaluated in large-scale prospective randomized
studies.
Thanks to the highly selective effects of mela-
tonin on its receptors and therefore an excellent
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safety profile, it is well tolerated (92). However,
more studies are required to be carried out in order
to shed light on the possibility of its application in
the context of PCOS.
Figure 2. The role of melatonin in the pathogenesis of PCOS.
4. Discussion
The current review summarizes the role of mela-
tonin in the pathogenesis of PCOS and the protec-
tive effects of exogenous melatonin administration
in the regulation of reproductive function in the
context of PCOS. Melatonin levels in serum and
follicular fluid of PCOS patients are different from
healthy women. In PCOS patients, melatonin level
in serum is usually higher than in healthy women,
which is considered as a sign of diagnosing PCOS
(32). But a reverse condition occurs in melatonin
level of follicular fluid. Due to fewer uptakes of
melatonin in ovarian follicle in PCOS patients
against healthy women, follicular fluid contains
lesser melatonin level compared to the healthy
condition (32). Melatonin seems to promote follicu-
lar maturation and ovulation through the protection
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of follicles against oxidative stress and their rescue
form atresia (40). Furthermore, melatonin showed
protective effects on corpus luteum against ROS
via its antioxidant effects (76). Melatonin level
in follicular fluid of PCOS women is notably
lower than in healthy women, which is related
to the ovulation problems. It has been reported
that melatonin administration can compensate the
reduction of this hormone in follicular fluid and
can halt ovulation problems (32). Melatonin treat-
ment indicated protective effects against metabolic
and reproductive abnormalities in PCOS patients.
Melatonin administration in PCOS patients sig-
nificantly affects body characteristics including
reduced body weight, body mass index and intra-
abdominal fat (56). During the ovulatory process,
ROS are produced within the follicles; for this rea-
son, the scavenging activity of melatonin plays an
important role during ovulation. Melatonin reduces
oxidative stress and causes oocyte maturation and
luteinization of GC making it as an effective treat-
ment for PCOS patients. Intra-follicular melatonin
concentration was considerably lower in PCOS
patients giving rise to anovulation and poor oocyte
quality in these patients. The administration of
melatonin alone or in combination with other drugs
in PCOS women has been shown to increase the
intrafollicular melatonin concentration, reduce the
intrafollicular oxidative stress, and also increases
the fertilization and pregnancy rates. Melatonin
also improves the production of progesterone from
corpus luteum in PCOS patients. The deficiency of
melatonin alters gonadotrophin secretion, reduces
the synthesis of FSH, and increases the synthesis
of LH, the latter being the major change detected
in PCOS patients (77). Melatonin can adjust the
hypothalamic axis by inhibiting the release of hor-
mones such as FSH, which leads to the reduction
of cystic follicles. Melatonin can also regulate the
synthesis of GnRH through its receptors in the
granulosa-luteal cells via inhibiting GnRH receptor
expression and sustaining the corpus luteumwhich
maintains progesterone secretion (93).
5. Conclusion
In summary, metabolic dysfunction is the major
finding contributing to the initiation of PCOS, mela-
tonin can hinder this process via its improving
effects on metabolic functions. Melatonin treat-
ment in PCOS patients can enhance the quality
of the oocyte and embryo, increase the number
of mature oocytes, reduce obesity, and ameliorate
the proinflammatory state, which underlies the
development of insulin resistance.
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